LHX2 Inhibitors
LHX2 inhibitors are a class of chemical compounds that specifically target the LHX2 protein, a transcription factor belonging to the LIM homeobox family. LHX2 plays a crucial role in regulating gene expression during developmental processes, particularly in tissues such as the brain, hair follicles, and the immune system. As a transcription factor, LHX2 binds to specific DNA sequences, controlling the expression of genes involved in cell differentiation, proliferation, and organogenesis. Inhibitors of LHX2 disrupt its ability to bind to DNA or interact with other transcriptional regulators, leading to alterations in gene expression programs that are crucial for proper cellular development and differentiation.
The mechanism of action of LHX2 inhibitors typically involves either direct binding to the DNA-binding domain of the LHX2 protein or interfering with its interaction with co-factors that are necessary for transcriptional regulation. By blocking these functions, LHX2 inhibitors prevent the transcription factor from activating or repressing target genes, thereby disrupting the cellular pathways that depend on its regulatory activity. These inhibitors are important tools for studying the role of LHX2 in developmental biology and for understanding the molecular mechanisms that govern the differentiation and function of various tissues. By inhibiting LHX2, researchers can explore the intricate network of genes controlled by this transcription factor and gain insights into how transcriptional regulation influences key biological processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3 kinase inhibitor that modulates the PI3K/AKT pathway. By blocking PI3 kinase activity, it disrupts downstream signaling cascades. LHX2, associated with neural development, can be indirectly influenced, as the PI3K/AKT pathway plays a crucial role in neural differentiation and progenitor cell fate determination. Wortmannin's impact on this pathway can thus modulate LHX2 expression. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, dampens the MAPK pathway. LHX2, implicated in embryonic development, is indirectly affected, as the MAPK pathway is integral to cell proliferation and differentiation during development. Modulation of MAPK signaling by Trametinib can consequently influence LHX2 expression, impacting its role in neural and tissue development. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src family kinase inhibitor, disrupts Src-dependent signaling. LHX2, involved in neural crest cell migration, can be indirectly affected, as Src kinases contribute to cell migration processes. Dasatinib's impact on Src-dependent pathways can modulate LHX2 expression, potentially influencing neural crest cell migration during embryonic development. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that modulates the p38 MAPK signaling pathway. LHX2, associated with neural tube development, can be indirectly influenced, as p38 MAPK plays a role in neural tube closure. SB203580's impact on the p38 MAPK pathway can thus modulate LHX2 expression, affecting its involvement in neural tube closure during embryogenesis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3 kinase, affecting the PI3K/AKT pathway. LHX2, involved in neural differentiation, can be indirectly influenced, as the PI3K/AKT pathway is crucial for neurogenesis. LY294002's impact on this pathway can modulate LHX2 expression, potentially impacting neural differentiation processes during embryonic development. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 796 is a p38 MAPK inhibitor affecting the p38 MAPK pathway. LHX2, implicated in neurogenesis, can be indirectly influenced, as p38 MAPK contributes to neural progenitor cell proliferation. BIRB 796's impact on the p38 MAPK pathway can thus modulate LHX2 expression, affecting its role in regulating neural progenitor cell fate. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK1/2 inhibitor, modulates JAK-STAT signaling. LHX2, associated with neural crest development, can be indirectly affected, as JAK-STAT pathways play a role in cell fate determination. Ruxolitinib's impact on JAK-STAT signaling can modulate LHX2 expression, influencing neural crest cell fate decisions during embryonic development. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, influencing the mTOR signaling pathway. LHX2, implicated in neural development, can be indirectly affected, as mTOR signaling plays a role in neural progenitor cell proliferation and differentiation. Rapamycin's impact on the mTOR pathway can modulate LHX2 expression, affecting its involvement in neural progenitor cell fate determination. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 inhibits AKT, affecting the PI3K/AKT pathway. LHX2, involved in neural differentiation, can be indirectly influenced, as the PI3K/AKT pathway is crucial for neurogenesis. AZD5363's impact on this pathway can modulate LHX2 expression, potentially impacting neural differentiation processes during embryonic development. | ||||||